Abstract
BackgroundThe use of platelet lysate (PL) for the ex-vivo expansion of mesenchymal stromal/stem cells (MSCs) was initially proposed by Doucet et al. in 2005, as an alternative to animal serum. Moreover, regulatory authorities discourage the use of fetal bovine serum (FBS) or other animal derivatives, to avoid risk of zoonoses and xenogeneic immune reactions. Even if many studies investigated PL composition, there still are some open issues related to its use in ex-vivo MSC expansion, especially according to good manufacturing practice (GMP) grade protocols.MethodsAs an authorized cell factory, we report our experience using standardized PL produced by Azienda Ospedaliero Universitaria Meyer Transfusion Service for MSC expansion according to a GMP grade clinical protocol. As suggested by other authors, we performed an in-vitro test on MSCs versus MSCs cultured with FBS that still represents the best way to test PL batches. We compared 12 MSC batches cultured with DMEM 5% PL with similar batches cultured with DMEM 10% FBS, focusing on the MSC proliferation rate, MSC surface marker expression, MSC immunomodulatory and differentiation potential, and finally MSC relative telomere length.ResultsResults confirmed the literature data as PL increases cell proliferation without affecting the MSC immunophenotype, immunomodulatory potential, differentiation potential and relative telomere length.ConclusionsPL can be considered a safe alternative to FBS for ex-vivo expansion of MSC according to a GMP grade protocol. Our experience confirms the literature data: a large number of MSCs for clinical applications can be obtained by expansion with PL, without affecting the MSC main features. Our experience underlines the benefits of a close collaboration between the PL producers (transfusion service) and the end users (cell factory) in a synergy of skills and experiences that can lead to standardized PL production.
Highlights
The use of platelet lysate (PL) for the ex-vivo expansion of mesenchymal stromal/stem cells (MSCs) was initially proposed by Doucet et al in 2005, as an alternative to animal serum
As an Agenzia italiana del Farmaco (AIFA) authorized cell factory, we report our experience in using PL produced by Azienda Ospedaliero Universitaria (AOU) Meyer Transfusion Service for bone marrow (BM)-MSC expansion according to a good manufacturing practice (GMP) grade protocol
Fetal bovine serum, MSC mesenchymal stromal/stem cell, PL platelet lysate for example, some proposals might include a multiplex assay for simultaneous detection and quantification of cytokines, chemokines and growth factors in each PL batch produced
Summary
The use of platelet lysate (PL) for the ex-vivo expansion of mesenchymal stromal/stem cells (MSCs) was initially proposed by Doucet et al in 2005, as an alternative to animal serum. Mesenchymal stromal/stem cells (MSCs) represent one of the most promising tools in cellular therapy and regenerative medicine due to their immunomodulatory and regenerative properties [1,2,3,4,5,6,7]. Another emerging clinical application of mesenchymal stromal cells is represented by the targeted delivery of chemotherapeutic agents to neoplastic cells, maximizing the cytotoxic. FBS has a poorly characterized composition, it can be a source of xenogenic antigens and zoonotic infections, and the lack of standardization of FBS preparations may affect cell culture performance [16]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have